Log-in / Create Account  
Session Information
2008 BIO International Convention
Click here to go to the previous page
Investment in Diagnostics for Personalized Medicine
Track : Devices and Predictive Diagnostics
Program Code: 866
Date: Wednesday, June 18, 2008
Time: 8:15 AM to 9:45 AM  EST
Location: 27AB
CHAIR :
Roger O'Sullivan, JD, Member , O'Sullivan PLLC
SPEAKER (S):
Philippe Chambon, PhD, MD, Managing Director , New Leaf Partners, LLC
Fred Cohen, PhD, MD, General Partner , TPG Ventures, Inc.
Bill Ericson, JD, General Partner , Mohr, Davidow Ventures
Brad Margus, Chief Executive Officer , Perlegen Sciences, Inc
Randy Scott, PhD, Chairman & CEO , Genomic Health, Inc
Description
Corporate executives and venture capitalists will consider the major issues that will determine the development of the market for personalized medicine and targeted therapeutics. Successful business models will be examined and key factors in attracting institutional investors considered.

Objective1: Explore recent developments in the commercial and regulatory environments for these products.

Objective2: Examine specific business models and thereby impart to participants possible strategies for commercial success.

Objective3: "Consider factors that venture capitalists consider in making investment decisions in this market."


Streaming Audio with
PowerPoint Slides
(Code: 866)
  
This session is a part of:
2008 BIO International Convention Complete Session Set
Devices and Predictive Diagnostics Track